AAAAAA

   
Results: 1-19 |
Results: 19
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study
Authors: Alexopoulos, A Kouroussis, C Malamos, N Kakolyris, S Kalbakis, K Kosmas, C Mavroudis, D Agelaki, S Vlachonicolis, J Sarra, E Rigatos, G Georgoulias, V
Citation: A. Alexopoulos et al., Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study, ANN ONCOL, 12(6), 2001, pp. 793-798
Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study
Authors: Kakolyris, S Mavroudis, D Tsavaris, N Souglakos, J Tsiafaki, P Kalbakis, K Agelaki, S Androulakis, N Georgoulias, V
Citation: S. Kakolyris et al., Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study, ANN ONCOL, 12(2), 2001, pp. 193-197
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer
Authors: Stathopoulos, GP Mavroudis, D Tsavaris, N Kouroussis, C Aravantinos, G Agelaki, S Kakolyris, S Rigatos, SK Karabekios, S Georgoulias, V
Citation: Gp. Stathopoulos et al., Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer, ANN ONCOL, 12(1), 2001, pp. 101-103
A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors
Authors: Kouroussis, C Kakolyris, S Mavroudis, D Androulakis, N Kalbakis, K Agelaki, S Sarra, E Souglakos, J Christodoulakis, M Samonis, G Georgoulias, V
Citation: C. Kouroussis et al., A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors, AM J CL ONC, 24(4), 2001, pp. 404-407
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer
Authors: Agelaki, S Kakolyris, S Palamidas, P Kouroussis, C Mavroudis, D Kalbakis, K Georgoulias, V Raptis, A
Citation: S. Agelaki et al., A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer, LUNG CANC, 34(1), 2001, pp. 133-139
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study
Authors: Kakolyris, S Papadakis, E Tsiafaki, X Kalofonos, C Rapti, A Toubis, M Bania, E Kouroussis, C Chainis, K Androulakis, N Agelaki, S Sarra, E Vardakis, N Georgoulias, V
Citation: S. Kakolyris et al., Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study, LUNG CANC, 32(2), 2001, pp. 179-187
A phase I clinical trial of topotecan given every 2 weeks in patients withrefractory solid tumors
Authors: Kakolyris, S Kouroussis, C Souglakos, J Mavroudis, D Agelaki, S Kalbakis, K Androulakis, N Vardakis, N Vamvakas, L Georgoulias, V
Citation: S. Kakolyris et al., A phase I clinical trial of topotecan given every 2 weeks in patients withrefractory solid tumors, ONCOL-BASEL, 61(4), 2001, pp. 265-270
Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: Two parallel multicenter phase II trials
Authors: Agelaki, S Bania, H Kouroussis, C Blazoyiannakis, G Sougalkos, J Tsiafaki, X Harpidou, A Kalbakis, K Rapti, A Androulakis, N Sarra, E Georgoulias, V Papadakis, E
Citation: S. Agelaki et al., Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: Two parallel multicenter phase II trials, ONCOL-BASEL, 60(3), 2001, pp. 235-241
Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuousinfusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
Authors: Kalbakis, K Kouroussis, C Kakolyris, S Mavroudis, D Souglakos, J Agelaki, S Vamvakas, L Christodoulakis, M Stylianou, K Georgoulias, V
Citation: K. Kalbakis et al., Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuousinfusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes, BR J CANC, 85(6), 2001, pp. 798-802
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study
Authors: Giannakakis, T Ziras, N Kakolyris, S Mavroudis, D Androulakis, N Agelaki, S Parashos, M Sarra, E Dimou, T Hatzidaki, D Vlachonikolis, J Georgoulias, V
Citation: T. Giannakakis et al., Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study, EUR J CANC, 36(6), 2000, pp. 742-747
Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study
Authors: Mavroudis, D Alexopoulos, A Ziras, N Malamos, N Kouroussis, C Kakolyris, S Agelaki, S Kalbakis, K Tsavaris, N Potamianou, A Rigatos, G Georgoulias, V
Citation: D. Mavroudis et al., Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study, ANN ONCOL, 11(10), 2000, pp. 1249-1254
A dose escalation study of weekly docetaxel in patients with advanced solid tumors
Authors: Kouroussis, C Agelaki, S Mavroudis, D Souglakos, J Kakolyris, S Kalbakis, K Vardakis, N Reppa, D Hatzidaki, D Samonis, G Georgoulias, V
Citation: C. Kouroussis et al., A dose escalation study of weekly docetaxel in patients with advanced solid tumors, CANC CHEMOT, 46(6), 2000, pp. 488-492
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF) - A phase II trial
Authors: Mavroudis, D Kourousis, C Androulakis, N Kalbakis, K Agelaki, S Kakolyris, S Souglakos, J Sarra, E Vardakis, N Hatzidaki, D Sarmonis, G Georgoulias, V
Citation: D. Mavroudis et al., Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF) - A phase II trial, AM J CL ONC, 23(4), 2000, pp. 341-344
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy
Authors: Kakolyris, S Souglakos, J Agelaki, S Kourousis, C Mavroudis, D Sarra, E Malliotakis, P Georgoulias, V
Citation: S. Kakolyris et al., A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy, LUNG CANC, 30(3), 2000, pp. 193-198
Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report
Authors: Mavroudis, D Kourousis, C Kakolyris, S Agelaki, S Kalbakis, K Androulakis, N Souglakos, J Vardakis, N Samonis, G Georgoulias, V
Citation: D. Mavroudis et al., Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report, SEMIN ONCOL, 27(1), 2000, pp. 25-30
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study
Authors: Kouroussis, C Xydakis, E Potamianou, A Giannakakis, T Kakolyris, S Agelaki, S Sara, E Malamos, N Alexopoulos, A Mavroudis, D Samonis, G Papadouris, S Georgoulias, V Panagos, G
Citation: C. Kouroussis et al., Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study, ANN ONCOL, 10(5), 1999, pp. 547-552
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial
Authors: Mavroudis, D Malamos, N Alexopoulos, A Kourousis, C Agelaki, S Sarra, E Potamianou, A Kosmas, C Rigatos, G Giannakakis, T Kalbakis, K Apostolaki, F Vlachonicolis, J Kakolyris, S Samonis, G Georgoulias, V
Citation: D. Mavroudis et al., Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial, ANN ONCOL, 10(2), 1999, pp. 211-215
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin
Authors: Kakolyris, S Kourousis, C Koukourakis, M Androulakis, N Vamvakas, L Agelaki, S Hatzidaki, D Samonis, G Tsiftsis, D Georgoulias, V
Citation: S. Kakolyris et al., First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin, AM J CL ONC, 22(6), 1999, pp. 568-572
First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrolacetate in advanced breast cancer
Authors: Kakolyris, S Samonis, G Koukourakis, M Vlachonicolis, J Kalbakis, K Agelaki, S Chalkiadakis, G Sanidas, E Tsiftsis, D Georgoulias, V
Citation: S. Kakolyris et al., First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrolacetate in advanced breast cancer, AM J CL ONC, 22(3), 1999, pp. 273-277
Risultati: 1-19 |